Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan
Topics & Concepts
PlaceboTolerabilitySchizophrenia (object-oriented programming)AntipsychoticAdverse effectMedicinePositive and Negative Syndrome ScaleAgonistPsychosisMuscarinic acetylcholine receptorAnticholinergicPsychologyAnesthesiaInternal medicinePharmacologyPsychiatryReceptorAlternative medicinePathologyReceptor Mechanisms and SignalingSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior